Chris Ogden, consultant uro-oncologist is a pioneer of robotic surgery in the UK and ‘one of the worlds leading robotic surgeons’ (BBC Horizon).
Da Vinci nerve sparing robotic prostate surgery
High intensity focused ultrasound (HIFU) for prostate cancer
He has the longest and largest series of radical robotic prostatectomies in the UK, with thousands of robotic prostatectomies (Mail on Sunday August 2017). Mr Ogden is a high volume surgeon performing over a hundred operations a year. He was recruited to The Royal Marsden hospital in 2006 to set up and lead the robotic prostatectomy program. He was attracted to the hospital as a keen advocate of ‘active surveillance’ for prostate cancer, which was invented at the Marsden.
Chris Ogden was the first UK urologist to present a peer reviewed paper at the national congress BAUS on 100 consecutive robotic prostate operations with full oncological and functional outcomes. His paper on his long term results of robotic prostate surgery was accepted and presented at the American Urological Association (AUA) Congress Meeting and awarded the prize for best paper. He is the first urologist in the world to compare consecutive cases of the ground breaking technologies of HIFU (High Intensity Focused Ultrasound) and robotics, presenting at the UK annual conference. He has been a part of the development of Focal day case surgery for treating certain forms of prostate cancer, completing the multi centre INDEX study into the effectiveness of focal therapy, due to be published in 2017.
Chris Ogden was the first UK urologist to present the UK experience to the fledgling European Robotic Urological Society and the American Urological Society; also presenting the first one hundred, then 500, robotic cases with outcome to the British Urological Society; as well as the only clinical comparison between whole gland HIFU and Robotic prostatectomy, the two novel competing technologies at that time. This comparison showed that whole gland HIFU delivered the perfect trifecta outcome in a third of patients, but that overall robotic surgical removal had the edge. He has been a part of the development of Focal day case surgery for treating certain forms of prostate cancer, completing the multi centre INDEX study into the effectiveness of focal therapy, published in 2017.
The national AUDIT for radical prostatectomy within British Urology (BAUS) was made public for the first time in 2015. More recently the three year data outcomes for 2015, 2016 and 2017 have been analysed. The data shows that Mr Ogden is one of the few high volume surgeons in robotic prostate surgery (more than 100 cases a year). In this national analysis, he has had no serious complications (Clavian III or above) and zero transfusion rate.
Clinically meaningful parameters of surgical outcome measures is the unfavourable positive surgical margin (+ve SM) as well as a detectable rising PSA post prostate removal: the biochemical reoccurrence rate (BCR).
The three year BAUS national Audit data shows that although Mr Ogden’s practice encompasses a higher percentage of more aggressive cancer, T3 or above (53% versus the national average of 45.83%), he demonstrated an overall personal unfavourable cancer surgical margin rate of 11.8% compared to the overall national surgical margin rate of 26.3%.
His most recent annual review (2019, before the effect of Covid -19 in 2020) of his HCA and private radical prostatectomies show an unfavourable surgical margin rate of 8%; and a BCR of 6%.
Mr Ogden’s results are equivalent to the best published results of the world leading robotic prostate surgeons: for cancer margins (clearance), urinary continence and sexual function.